| Original language | English |
|---|---|
| Pages (from-to) | 368-370 |
| Number of pages | 3 |
| Journal | Journal of Thoracic Oncology |
| Volume | 16 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 Mar 2021 |
| Externally published | Yes |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Thoracic Oncology, Vol. 16, No. 3, 01.03.2021, p. 368-370.
Research output: Contribution to journal › Editorial
TY - JOUR
T1 - Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC
AU - Remon, Jordi
AU - Hendriks, Lizza E.L.
N1 - Funding Information: Disclosure: Dr. Remon reports receiving other fees from Merck Sharp & Dohme, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, AstraZeneca, Roche, and personal and other fees from OSE Immunotherapeutics outside of the submitted work. Dr. Hendriks reports receiving other fees from Boehringer Ingelheim, Bristol-Myers Squibb, Roche Genentech, AstraZeneca, Eli Lilly, Pfizer, Merck Sharp & Dohme, Takeda, and Amgen; grants from Roche Genentech, Boehringer Ingelheim AstraZeneca; personal fees from Quadia; and nonfinancial support from AstraZeneca, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme/Merck, GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, and Mirati outside of the submitted work. Funding Information: Disclosure: Dr. Remon reports receiving other fees from Merck Sharp & Dohme , Boehringer Ingelheim, Pfizer , Bristol-Myers Squibb , AstraZeneca , Roche , and personal and other fees from OSE Immunotherapeutics outside of the submitted work. Dr. Hendriks reports receiving other fees from Boehringer Ingelheim, Bristol-Myers Squibb , Roche Genentech, AstraZeneca , Eli Lilly , Pfizer , Merck Sharp & Dohme , Takeda, and Amgen ; grants from Roche Genentech, Boehringer Ingelheim AstraZeneca; personal fees from Quadia; and nonfinancial support from AstraZeneca , Novartis , Bristol-Myers Squibb , Merck Sharp & Dohme / Merck , GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, and Mirati outside of the submitted work.
PY - 2021/3/1
Y1 - 2021/3/1
UR - http://www.scopus.com/inward/record.url?scp=85101599700&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2020.11.027
DO - 10.1016/j.jtho.2020.11.027
M3 - Editorial
C2 - 33641720
AN - SCOPUS:85101599700
SN - 1556-0864
VL - 16
SP - 368
EP - 370
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 3
ER -